See every side of every news story
Published loading...Updated

Heidelberg Pharma announces financial figures and reports on successful business performance in 2024 – Optimum Strategic Communications

Summary by Optimum Strategic Communications
Promising data in the clinical trial with HDP-101 in multiple myeloma, including a complete remission in one patient; study progressing well First approvals for clinical trial with ATAC candidate HDP-102 received; study start soon Financial figures in line with plan with improved operating result and lower cash requirements Payment of USD 20 million from HealthCare […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Optimum Strategic Communications broke the news in on Friday, March 21, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.